IN2012DN02632A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02632A
IN2012DN02632A IN2632DEN2012A IN2012DN02632A IN 2012DN02632 A IN2012DN02632 A IN 2012DN02632A IN 2632DEN2012 A IN2632DEN2012 A IN 2632DEN2012A IN 2012DN02632 A IN2012DN02632 A IN 2012DN02632A
Authority
IN
India
Prior art keywords
hydroxyl
hydrogen
optionally substituted
hydrocarbon group
group optionally
Prior art date
Application number
Other languages
English (en)
Inventor
Shunsuke Iriyama
Hirotada Fukunishi
Masaru Suetsugu
Satoshi Amano
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Publication of IN2012DN02632A publication Critical patent/IN2012DN02632A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
IN2632DEN2012 2009-09-30 2010-09-29 IN2012DN02632A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009228406 2009-09-30
PCT/JP2010/066998 WO2011040496A1 (ja) 2009-09-30 2010-09-29 ヘパラナーゼ活性阻害剤

Publications (1)

Publication Number Publication Date
IN2012DN02632A true IN2012DN02632A (nl) 2015-09-04

Family

ID=43826308

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2632DEN2012 IN2012DN02632A (nl) 2009-09-30 2010-09-29

Country Status (12)

Country Link
US (2) US8609075B2 (nl)
EP (1) EP2484359B1 (nl)
JP (2) JP5593323B2 (nl)
KR (1) KR101431348B1 (nl)
CN (1) CN102655863B (nl)
BR (1) BR112012007090A2 (nl)
ES (1) ES2687780T3 (nl)
HK (1) HK1171390A1 (nl)
IN (1) IN2012DN02632A (nl)
RU (1) RU2503454C1 (nl)
TW (1) TWI461221B (nl)
WO (1) WO2011040496A1 (nl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5685369B2 (ja) * 2009-09-15 2015-03-18 株式会社 資生堂 ヘパラナーゼ阻害剤による美白方法及び美白効果を有する物質の評価方法
JP2013032332A (ja) * 2011-07-01 2013-02-14 Lintec Corp 免疫賦活剤
JP5258993B1 (ja) * 2012-03-29 2013-08-07 株式会社 資生堂 ヘパラン硫酸産生促進剤
JP6321506B2 (ja) * 2014-09-22 2018-05-09 株式会社 資生堂 ヘパラナーゼ阻害剤による美白方法及び美白効果を有する物質の評価方法
KR20190066001A (ko) * 2016-10-21 2019-06-12 가부시키가이샤 시세이도 라미닌 511 생성 촉진제, 표피 기저막 안정화제 및/또는 표피 줄기 세포 감소 억제 또는 증가 촉진제의 스크리닝 방법
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3381898A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Symmetrical tris-aryl-amide derivatives and their use as anti-heparanase
EP3381908A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase
EP3381907A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Symmetrical 2-aminophenyl-benzazolyl-5-acetate compounds and their use as anti-heparanase
EP3381897A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer
EP3381906A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Compounds for use as heparanase inhibitors
EP3388439A1 (en) 2017-04-11 2018-10-17 Leadiant Biosciences SA Biotin-conjugated n-acetyl glycol split heparin
AU2018282841B2 (en) 2017-06-13 2024-03-28 National Cancer Center Carcinogenesis inhibitor
US20220202964A1 (en) * 2019-04-24 2022-06-30 University Of Florida Research Foundation, Incorporated Heparanase compounds and methods of use
CN116615196A (zh) * 2020-12-15 2023-08-18 株式会社资生堂 真皮再生促进剂
US20230404885A1 (en) 2020-12-15 2023-12-21 Shiseido Company, Ltd. Epidermal stem cell proliferation-promoting agent
EP4442324A1 (en) 2021-12-02 2024-10-09 Shiseido Company, Ltd. Cosmetic
CN118201590A (zh) * 2021-12-03 2024-06-14 株式会社资生堂 化妆品
JPWO2023106121A1 (nl) * 2021-12-09 2023-06-15
JPWO2023106123A1 (nl) * 2021-12-09 2023-06-15
CN118265517A (zh) * 2021-12-20 2024-06-28 株式会社资生堂 水包油型乳化化妆品
WO2023149226A1 (ja) 2022-02-03 2023-08-10 株式会社 資生堂 皮膚外用組成物
CN118524825A (zh) 2022-02-03 2024-08-20 株式会社资生堂 皮肤外用组合物
JPWO2023149225A1 (nl) 2022-02-03 2023-08-10

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1256235A (en) * 1917-03-31 1918-02-12 William F Jacobs Work-supporting horse.
US4049650A (en) 1976-10-18 1977-09-20 Morton-Norwich Products, Inc. 1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones
US4731453A (en) 1985-04-03 1988-03-15 Mitsui Toatsu Chemicals, Inc. Process for producing 1, 3-dialkyl-2-imidazolidinone
US4593038A (en) * 1985-04-03 1986-06-03 Burzynski Stanislaw R Topical use of 3-phenylacetylamino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation
US4960771A (en) 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5011621A (en) 1990-06-04 1991-04-30 Arco Chemical Technology, Inc. Paint stripper compositions containing N-methyl-2-pyrrolidone and renewable resources
US5583256A (en) 1994-07-07 1996-12-10 Mitsui Toatsu Chemicals, Inc. Process for producing 1,3-dialkyl-2-imidazolidinone
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester
US5837224A (en) 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
JPH11335235A (ja) 1998-05-22 1999-12-07 Shiseido Co Ltd 抗老化剤
GB9913415D0 (en) 1999-06-10 1999-08-11 Central Manchester Healthcare Heparanase assay
JP2001163794A (ja) 1999-12-03 2001-06-19 Shiseido Co Ltd ヒアルロン酸産生促進剤および皮膚外用剤
TWI233361B (en) 2001-04-13 2005-06-01 Gen Hospital Corp Methods of preventing UVB-induced skin damage
US20030129259A1 (en) * 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
ATE300280T1 (de) * 2002-02-15 2005-08-15 Goldschmidt Gmbh Verwendung von kreatinin und/oder kreatinin- derivaten zur aufhellung der haut und milderung von pigmentstörungen
JP5122060B2 (ja) 2002-06-25 2013-01-16 株式会社 資生堂 抗老化剤
MXPA06003163A (es) * 2003-09-23 2006-06-05 Novartis Ag Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico.
EP2065383A1 (en) * 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazole compounds and methods of use thereof as protein kinase inhibitors
FR2873377B1 (fr) * 2004-07-23 2006-10-13 Sanofi Synthelabo Derives d'azasucre, inhibiteurs d'heparanases, leur procede de preparation, les compositions en contenant et leur utilisation
US7238260B2 (en) 2004-10-26 2007-07-03 Lyondell Chemical Technology, L.P. Purification of N-(2-hydroxyethyl)-2-pyrrolidone
JP2006303185A (ja) 2005-04-20 2006-11-02 Matsushita Electric Ind Co Ltd 半導体装置及びその製造方法
JP2007277149A (ja) 2006-04-06 2007-10-25 Kao Corp インボルクリン発現促進剤
US8097581B2 (en) * 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
CN101311188B (zh) * 2007-05-21 2010-12-29 中国人民解放军军事医学科学院生物工程研究所 人乙酰肝素酶的小分子多肽抑制剂
JP5179096B2 (ja) 2007-06-08 2013-04-10 株式会社 資生堂 コーニファイドエンベロープ形成・成熟化促進剤
JP2008303187A (ja) 2007-06-08 2008-12-18 Shiseido Co Ltd コーニファイドエンベロープ形成・成熟化促進剤
JP5105962B2 (ja) * 2007-06-08 2012-12-26 株式会社 資生堂 コーニファイドエンベロープ形成・成熟化促進剤
WO2009122540A1 (ja) 2008-03-31 2009-10-08 株式会社資生堂 しわを防止または改善するための経口、注射、皮膚外用剤および美容方法
EP2987536A1 (en) 2008-03-31 2016-02-24 Shiseido Co., Ltd. Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles
FR2931064B1 (fr) 2008-05-14 2010-08-13 Oreal Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone; procede de photostabilisation du derive de dibenzoylmethane

Also Published As

Publication number Publication date
KR20120060205A (ko) 2012-06-11
AU2010301641A1 (en) 2012-03-22
US20120183481A1 (en) 2012-07-19
JP5593323B2 (ja) 2014-09-24
HK1171390A1 (en) 2013-03-28
TW201117832A (en) 2011-06-01
EP2484359A4 (en) 2015-07-08
CN102655863A (zh) 2012-09-05
WO2011040496A1 (ja) 2011-04-07
US8609075B2 (en) 2013-12-17
US20140080878A1 (en) 2014-03-20
JP2014111640A (ja) 2014-06-19
KR101431348B1 (ko) 2014-08-19
US8901160B2 (en) 2014-12-02
ES2687780T3 (es) 2018-10-29
RU2012117797A (ru) 2013-11-10
RU2503454C1 (ru) 2014-01-10
EP2484359A1 (en) 2012-08-08
CN102655863B (zh) 2013-11-20
EP2484359B1 (en) 2018-07-25
BR112012007090A2 (pt) 2018-06-05
TWI461221B (zh) 2014-11-21
JPWO2011040496A1 (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
IN2012DN02632A (nl)
MX338707B (es) Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
MX2016007661A (es) Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo.
PH12015502514A1 (en) An amorphous and crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
GEP20156309B (en) Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
IN2012DN01350A (nl)
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
MY155658A (en) A-isopropylphenyl glucitol compounds as sglti inhibitors
MX2014000452A (es) Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk).
GB2515909A (en) Polymer
IN2012DN00694A (nl)
NO20091746L (no) Nytt difenylazetidinon substituert med piperazin-1-sulfonsyre med forbedrede farmakologiske egenskaper
RS53900B1 (en) CRYSTAL FORMS OF HYDROCHLORIDE SALTS (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOL-5-CARBONYL) -2,3,4,4A, 9,9A-HEXAHIDRO-1H-INDENO [2,1-B] PIRIDIN-6-CARBONITRILA AND THEIR USE AS A HSD INHIBITOR 1
MX2013012982A (es) Metodo para promover el crecimiento de plantas.
RS53152B (en) NEW ANTIBACTERIAL AGENTS FOR TREATMENT OF Gram POSITIVE INFECTIONS
MY194452A (en) 1,4-Butanediol-Containing Composition
UA107831C2 (en) Composition for combating plant diseases and its application
WO2012024397A3 (en) 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BR112014015430A8 (pt) formulação oftálmica
MY179437A (en) Preventing or ameliorating agent for pigmentation
MX2011012537A (es) Agente para el tratamiento o prevencion de enfermedades asociadas con actividad de factores neurotroficos.
GEP20156295B (en) 1,4-oxazepane derivatives
TH124389B (th) สารยับยั้งเฮปาราเนส แอคตีวิตี้
MX355654B (es) Derivado de paroxetina.